Serum fibroblast growth factor 21: Lack of association with gestational diabetes and pregnancy outcomes

Table 4 Fibroblast growth factor 21 by quintile and selected pregnancy outcomes

Outcomes	Quintile of fibroblast growth factor 21 in pg/mL					P value
	1: 28.52-51.91	2: 53.4-59.23	3: 60.04–67.56	4: 68.24–76.70	5: 79.21-140.55
Maternal age in years	29.14 ± 4.56	30.19 ± 4.90	31.03 ± 4.82	29.05 ± 3.35	30.48 ± 4.17	0.810
Pre-pregnancy body mass index in kg/m2	22.97 (19.42–26.37)	23.00 (20.20-26.56)	20.50 (19.30-23.04)	21.80 (19.57-24.00)	22.50 (19.20-28.00)	0.370
Fasting glucose in mg/dL	77.50 (73.00-80.50)	79.50 (73.00-81.00)	76.50 (74.00-82.0)	77.50 (70.00-82.00)	78.50 (77.00-81.00)	0.990
Fasting insulin in μU/mL	8.57 (5.09-14.50)	9.93 (9.14-10.61)	7.76 (5.26-10.27)	5.08 (4.77-7.65)	8.89 (7.08-14.66)	0.200
Gestational diabetes mellitus	4 (19.05)	7 (33.33)	8 (38.10)	4 (19.05)	5 (23.81)	0.520
Pre-eclampsia	0 (0.00)	3 (14.29)	2 (9.52)	1 (4.76)	2 (9.52)	0.630
Birth weighting	3210 (295-3295)	3120 (2970-3380)	3060 (2820-3140)	3130 (2870-3335)	3025 (2890-3260)	0.400
Placental weighting	577.14 ± 94.01	608.89 ± 113.70	552.94 ± 97.52	555 ± 140.76	567.22 ± 196.79	0.740

Data are median (q₁-q₃), mean ± SD, or n (%).